Metabolic Damage Presents Differently in Young and Early-Aged C57BL/6 Mice Fed a High-Fat Diet  by Liu, Chia-Yuan et al.
ilable at ScienceDirect
International Journal of Gerontology 10 (2016) 105e111Contents lists avaInternational Journal of Gerontology
journal homepage: www.i jge-onl ine.comOriginal ArticleMetabolic Damage Presents Differently in Young and Early-Aged
C57BL/6 Mice Fed a High-Fat Diet*
Chia-Yuan Liu 1, 4, 6, 7 y, Ching-Wei Chang 1, 4, 6, 7 y, Hung-Chang Lee 2, 6, 7, 9 z, Yu-Jen Chen 3,
Tung-Hu Tsai 4, Jen-Shiu Chiang Chiau 5, Tsang-En Wang 1, 6, 7, Ming-Chieh Tsai 8,
Chun-Yan Yeung 2, 6, 7, Shou-Chuan Shih 1, 6, 7 * z
1 Division of Gastroenterology, Department of Internal Medicine, MacKay Memorial Hospital, 2 MacKay Children's Hospital, 3 Department of Radiation
Oncology, MacKay Memorial Hospital, 4 Institute of Traditional Medicine, National Yang-Ming University, 5 Department of Medical Research, Hsinchu
MacKay Memorial Hospital, Hsinchu, 6 Department of Medicine, MacKay Medical College, 7 Mackay Junior College of Medicine, Nursing, and Management,
New Taipei City, 8 Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital, 9 Department of Pediatrics, Hsinchu
MacKay Memorial Hospital, Hsinchu, Taiwana r t i c l e i n f o
Article history:
Received 10 January 2015
Received in revised form
7 October 2015
Accepted 22 October 2015
Available online 18 June 2016
Keywords:
aging,
high-fat diet,
metabolic damage,
mouse model,
obesity* Conﬂicts of interest: All contributing authors decla
of interest.
* Correspondence to: Shou-Chuan Shih, Div
Department of Internal Medicine, Mackay Memori
Chung-Shan North Road, Taipei, Taiwan. Tel.: þ886 2
25433642.
E-mail address: sschuan@mmh.org.tw (S.-C. Shih)
y These two authors contribute equally to this wor
z These two authors contribute equally to this wor
http://dx.doi.org/10.1016/j.ijge.2015.10.004
1873-9598/Copyright © 2016, Taiwan Society of Geria
CC BY-NC-ND license (http://creativecommons.org/lis u m m a r y
Background: Obesity in old individuals is increasing at alarming rates, and this population is more
vulnerable to the deleterious metabolic effects of obesity than younger individuals. However, at present,
there is no ideal obesity model to evaluate the interaction of aging and obesity.
Methods: The development of a metabolic damage model in response to a ﬁxed period of high-fat diet
(HFD) feeding was examined in mice of different ages. Mice aged 6 weeks (young group) and 44 weeks
(elderly group) were fed a standard diet or HFD for 12 weeks, and their metabolic characteristics were
studied. Inﬂammation was determined by the serum lipopolysaccharide (LPS) level. Gut microbiota
composition was analyzed from stool samples.
Results: After 12-week feeding, weight gain; elevated serum levels of cholesterol, triglyceride, and LPS;
increased homeostasis model assessment-estimated insulin resistance (HOMA-IR); fat accumulation;
nonalcoholic fatty liver disease (NAFLD) activity score (NAS); and gut microbiota changes occurred in
response to HFD feeding in both young and elderly groups (p< 0.05). HFD-induced serum levels of
alanine aminotransferase, cholesterol, triglyceride, and insulin; HOMA-IR; fat accumulation; NAS; and
gut microbiota changes were signiﬁcantly higher in the elderly group (p< 0.05).
Conclusion: Aging in an obese mouse model does not increase LPS but exacerbates NAFLD severity,
dyslipidemia, insulin insensitivity, fat accumulation, and gut microbiota changes. This obesity model
might help elucidate target or multiple organ alterations associated with metabolic disorder and aging.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
A global epidemic of obesity is expected to be the leading cause
of morbidity and mortality in the current and future generations.re that they have no conﬂicts
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tric Emergency & Critical Care Me
censes/by-nc-nd/4.0/).Obesity is a complex disorder involving excessive body fat. The
metabolic consequences of obesity drive life-threatening disorders,
including a spectrum of liver abnormalities such as nonalcoholic
fatty liver disease (NAFLD) and steatohepatitis and serious car-
diometabolic abnormalities, including Type 2 diabetes mellitus,
dyslipidemia, metabolic syndrome, hypertension, atherogenesis,
and coronary heart disease1,2.
By 2030e2035, 20% of American adults and 25% of European
adults will be 65 years or above3. The prevalence of obesity is rising
progressively among the older age groups as well. In the United
States, the prevalence of obesity in elderly Americans aged 60 years
or above increased from 23.6% in 1990 to 32.0% in 2000 and 37.4% in
2010. In Taiwan, a study on participants aged above 65 years indicine. Published by Elsevier Taiwan LLC. This is an open access article under the
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obese4. Obesity in the elderly is thus a matter of serious concern.
The aging process is altered or accelerated when car-
diometabolic diseases are present, and aging makes organisms
more susceptible to such illnesses. Both obesity and aging are
characterized by a low-grade inﬂammatory state and endocrine
changes3. Central and visceral obesities are more proinﬂammatory
than global obesity in elderly humans. The low-grade inﬂammatory
state is associated with decreased lean body mass, reduced im-
mune function, cognitive decline, insulin resistance, and several
correlates of metabolic control and insulin resistance such as
increased levels of tumor necrosis factor-a, interleukin-6, and C-
reactive protein. However, the precise role of aging in obesity and
related metabolic disorders is unclear.
Animal models can help elucidate the relationship between
aging, obesity, and metabolic disorders and can be used in phar-
macological studies. One advantage of animal models is having
precise control of factors. Furthermore, histological and biochem-
ical studies, which are difﬁcult to perform in humans, can be con-
ducted. Rodents are the most common laboratory animals used in
experimental models for the study of metabolic turnover of sub-
stances in the body5,6. To induce these metabolic disorders, various
dietary, genetic, and pharmacological models have been developed
at different ages. While many models display some of the signs of
metabolic damage, few models can adequately and fully mimic the
range of signs characterized in humans.
In this study, we sought to examine the potential effects of aging
on high-fat diet (HFD)-induced obesity and its metabolic damage.
We challenged mice of different ages with a deﬁned period of HFD,
a model that displays several correlations with human obesity.
2. Materials and methods
2.1. Animal models and diets
All experiments were approved by the Institutional Animal Care
and Use Committee protocol of theMacKayMemorial Hospital. Six-
week-old (young) male C57BL/6J mice were purchased from the
National Laboratory Animal Center (Taipei, Taiwan) and allowed
free access to standard chow (CHOW, 5010; LabDiet, PMI®Nutrition
International, LLC, Brentwood, MO, USA) until 44 weeks of age
(elderly)7. The lightedark cycle was 12:12, with a controlled envi-
ronment (23C, 50e60% relative humidity). Elderly (E) or young (Y)
mice (n¼ 6e10/group) were randomly divided into either CHOWor
HFD (45% Kcal, D12451; Research Diets, Inc., New Brunswick, NJ,
USA) groups for 12 weeks (Table 1).
2.2. Blood sampling and analysis
Mice were fasted overnight before anesthetization. Blood was
obtained by cardiac puncture and stored on ice for 30 minutes,
and then separated by centrifugation (1000 rpm, 15 minutes) toTable 1
Composition and energy content of the high-fat diet and standard chow.
Content (Kcal%)
HFD
Fat % 45.0
Protein % 20.0
CHO % 35.0
Energy content (Kcal/kg) 4730
Protein ingredients Casein, L-cysteine
Fat ingredients Soybean oil, lard
CHO ingredients Corn starch, maltodextr
CHO¼ carbohydrate; CHOW¼ standard chow; HFD¼ high-fat diet.obtain the serum. Levels of the following factors in serum were
determined using a dry chemistry analyzer (FUJI DRI-CHEM
NX500; Fujiﬁlm, Japan): alanine aminotransferase (ALT), total
cholesterol, and triglyceride. Enzyme-linked immunosorbent as-
says were performed for mouse insulin (EMD Millipore Co., USA)
and mouse lipopolysaccharides (LPSs; CUSABIO Biotech Co.,
China).
2.3. Radioimmunoassay for insulin and homeostasis model
assessment-estimated insulin resistance
For the fasting-based index, insulin sensitivity was calculated
from the homeostasis model assessment-estimated insulin resis-
tance (HOMA-IR) means of glucose and insulin values. HOMA-IR
was calculated using the following formula8: HOMA-IR ¼ [fasting
insulin (mU/mL)  fasting glucose (mM/L)]/22.5
2.4. Body fat and lean mass analysis
Micewere kept anesthetized with 2% isoﬂurane in oxygen at 2 L/
min on a scanning table. Fat and lean volumes in the anesthetized
mice were analyzed by high-resolution in vivo microcomputed to-
mography (micro-CT; SkyScan 1076, SkyScan, Bruker, Kontich,
Belgium) equipped with a tungsten target X-ray tube and a 0.5-mm
Al ﬁlter. The system was operated at 50 kVp and 150 mA electric
current. The equipment was adjusted to obtain the optimal trade-
off between adequate contrast and resolution of the fat or lean
deposits and a reasonable scan time. Total fat, visceral fat, and
subcutaneous fat areas in mice were analyzed on the images from
the level of the neck to the bottom using CTAn software (SkyScan,
Bruker)9.
2.5. Histopathological analysis of liver and adipose tissues
Liver and adipose tissues were ﬁxed in 10% buffered neutral
formalin and embedded in parafﬁn for subsequent hematox-
ylineeosin staining. Hepatic pathology of NAFLD was evaluated
based on the Kleiner Scoring System10. In brief, hematox-
ylineeosin-stained liver sections were scored for steatosis (0e3),
lobular inﬂammation (0e3), and hepatocyte ballooning (0e2). The
sum of these ﬁndings was used to determine the NAFLD activity
score (NAS).
2.6. Gut microbiota analysis
Stool was sampled at random from cages (n¼ 4/group) and
immediately stored at 20C for further analysis. The stool was
used for DNA extraction by the E.Z.N.A. stool DNA kit (Omega Bio-
tek, USA) according to the manufacturer’s instructions. The con-
centration was determined using a NanoDrop 2000 Spectropho-
tometer (Thermo Scientiﬁc). DNA detection and ampliﬁcation by
real-time quantitative polymerase chain reaction (PCR) wereDiets
CHOW
12.8
28.7
58.5
3080
Fish meal, yeast, alfalfa meal
Pork fat, soybean oil,
in, sucrose Corn starch, wheat, soybean, oats
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system software version 1.2.3 (Applied Biosystems). Bacteria,
including Bacteroidetes and Firmicutes, were detected by the
Maxima SYBR Green/ROX quantitative PCR Master Mix (Thermo
Scientiﬁc), with 100nM of each of the forward and reverse primers
and 1 ng DNA/reaction. PCRs were denatured at 95C for 2 minutes
and 95C for 10 minutes followed by 40 cycles of 95C for 15 sec-
onds and 60C for 1 minute. Melting curve analysis was performed
after ampliﬁcation11. From primer pairs targeting regions within
the 16S ribosomal RNA gene of various groups of gut bacteria12, two
primer pairs targeting the Firmicutes and Bacteroidetes were
chosen to assess and compare their relative abundances in the gut
microbiota of the mice. The relative gene ratio of Firmicutes and
Bacteroidetes was determined from stool samples.2.7. Statistical analysis
Results are presented as the mean with standard deviation.
Different superscript letters (a vs. b, a vs. c, a vs. d, b vs. c, b vs. d, and
c vs. d) indicate statistical signiﬁcance (p< 0.05) as determined by
one-way analysis of variance. Data were analyzed with IBM SPSS
software (Version 21.0; SPSS Institute, Chicago, IL, USA).Figure 1. Effects of aging on high-fat diet (HFD)-induced increases in body mass. (A)
Percentage weight gain from 12 weeks of standard chow (CHOW) or HFD feeding in
young (Y) and elderly (E) mice. (B) Weight gain per diet energy intake from the same
animals (n¼ 6/group). Different superscript letters (a vs. b, a vs. c, b vs. c) indicate
statistical signiﬁcance (p< 0.05).3. Results
3.1. Effects of aging on body weight and food intake
C57BL/6J mice were fed CHOW or HFD from 6 weeks and 44
weeks of age. These ages were selected to reﬂect the normal
physiology of young and old mice. The mice were killed for analysis
after 12 weeks on their respective diets at the ages of 18 weeks and
56 weeks. Weight gain occurred in young mice, but not in older
mice fed with CHOW (Figure 1A). The HFD induced a highly sig-
niﬁcant increase in body mass compared with CHOW feeding in
both young and elderly mice (p< 0.05), with the largest increase
occurring in the young mice (Figure 1A). The increase in body
weight in young mice on either diet was signiﬁcantly greater than
that in the elderly mice but did not reach statistical signiﬁcance
(Figure 1B). These two HFD-fed groups, therefore, had a marked
weight gain, which was not signiﬁcantly affected by aging. Food
intake was measured weekly, and energy intake in each group for
1 day/mouse was calculated. The mean energy intake did not differ
between the groups (data not shown).3.2. Effects of aging on fat mass
The effect of aging on visceral adipose tissue (VAT) mass was
examined. Mesenteric fat was evident in each group except the
CHOW group (Figure 2A). VAT mass in CHOW-fed mice tended to
increase with age, but the differences did not reach statistical sig-
niﬁcance (Figures 2A and 2B). Signiﬁcant increases in VAT mass
occurred with HFD feeding in both young and elderly groups
(Figure 2B; p< 0.05), and the increase was signiﬁcantly greater in
the old animals (Figure 2B). Micro-CT scanning showed that body
fat mass in CHOW-fed mice increased with age (Figures 2A and 2C).
Signiﬁcant increases in body fat mass occurred with HFD feeding in
both young and elderly groups (Figures 2A and 2C; p< 0.05), and
the increase was signiﬁcantly greater in the older animals
(Figure 2C). Therefore, both HFD-fed groups had a signiﬁcant in-
crease in body fat mass, which was also signiﬁcantly affected by
aging.3.3. Effects of aging on dyslipidemia in response to HFD
The serum cholesterol level increased signiﬁcantly (p< 0.05) in
both age groups with HFD feeding, and the increase was signiﬁ-
cantly greater in the old animals (Figure 3A; p< 0.05). Moreover,
the serum triglyceride level also increased signiﬁcantly in all age
groups with HFD feeding, and the increase was also signiﬁcantly
greater in the older group (Figure 3B; p< 0.05). Therefore, both
HFD-fed groups of mice had a signiﬁcant increase in dyslipidemia
that was also signiﬁcantly affected by aging.3.4. Effects of aging on insulin sensitivity
Hyperglycemia and hyperinsulinemia occurred with HFD
feeding in elderly groups. The serum glucose level was signiﬁcantly
higher (p< 0.05) in HFD-fed than CHOW-fed mice, but only in
elderly mice (Figure 3C). Serum insulin levels were also signiﬁ-
cantly elevated in HFD-fed than in CHOW-fed mice, but only in
elderly mice (Figure 3D; p< 0.05). Relative insulin sensitivity was
determined via HOMA. HOMA values increased in both HFD-fed
groups of mice, and the increase was signiﬁcantly greater in the
elderly group (Figure 3E). Both HFD-fed groups, therefore, had a
Figure 2. Effects of aging on high-fat diet (HFD)-induced increases in fat mass. (A) Gross adipose ﬁndings, body fat mass (white) micro-computed tomography (CT) images and
adipocytes of visceral adipose tissue (VAT) from 12 weeks of standard chow (CHOW) or HFD feeding in young (Y) and elderly (E) mice. (B) Percentage VAT and (C) percentage CT fat
from the same animals (n¼ 6/group). Different superscript letters (a vs. b, a vs. c, a vs. d, b vs. c, b vs. d, c vs. d) indicate statistical signiﬁcance (p< 0.05).
C.-Y. Liu et al.108signiﬁcant increase in insulin insensitivity that was also signiﬁ-
cantly affected by aging.
3.5. Steatohepatitis increases with aging
The effects of aging were examined on the development of
NAFLD, the hepatic manifestation of the metabolic syndrome. The
effect of aging on steatohepatitis was also assessed. Serum ALT
levels were signiﬁcantly elevated by HFD feeding in old mice
(p< 0.05) but not in young mice (Figure 4A). The ALT levels in the
HFD-fed oldmicewere also signiﬁcantly higher than those in young
HFD-fed animals (Figure 4A). No signiﬁcant increase in liver weight
occurred in either HFD-fed group (Figure 4B). The histological de-
gree of NAFLD demonstrated that the NAS was signiﬁcantly
increased with HFD feeding for both age groups (p< 0.05). The NAS
was also higher in the elderly group than in the young group
(p< 0.05; Figures 4C and 4D). Therefore, signiﬁcant liver injury
induced by the 12-week HFD was restricted to the older mice.
3.6. Aging promotes a low-grade inﬂammatory response to HFD
feeding
HFD-induced obesity is responsible for low-grade chronic
inﬂammation and metabolic endotoxemia on the serum LPS level.Here, we show that the serum LPS level increased signiﬁcantly
(p< 0.05) in both age groups with HFD feeding, but there was no
signiﬁcant difference between the young and elderly groups
(Figure 5). Thus, levels of LPS induced by the 12-week HFD feeding
were equivalent irrespective of age.
3.7. Aging alters gut microbiota composition in response to an HFD
Recent studies have highlighted the role of gut microbiota in the
development of obesity and metabolic syndrome. Gut microbiota
composition was determined by the Firmicutes-to-Bacteroidetes
(F/B) ratio. Here, we show that the F/B ratio increased signiﬁ-
cantly (p< 0.05) in both age groups with HFD feeding, and the in-
crease was signiﬁcantly greater in older groups (Figure 6). Thus,
both HFD-fed groups had a signiﬁcant increase in the F/B ratio that
was also signiﬁcantly affected by aging.
4. Discussion
This study demonstrates that both young and aged C57BL/6J
mice fed an HFD developed weight gain, insulin resistance, dysli-
pidemia, fat storage, and hepatic structural alterations character-
ized by steatosis, together with observed low-grade inﬂammation
and gut microbiota changes. Furthermore, aging accelerated or
Figure 3. Effects of aging on high-fat diet (HFD)-induced dyslipidemia and insulin resistance. Serum (A) cholesterol, (B) triglyceride, (C) glucose, and (D) insulin levels and (E)
homeostasis model assessment (HOMA) values from 12 weeks of standard chow (CHOW) or HFD feeding in young (Y) and elderly (E) mice (n¼ 6/group). Different superscript
letters (a vs. b, a vs. c, b vs. c) indicate statistical signiﬁcance (p< 0.05).
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mia, fat storage, and gut microbiota proﬁle.
Iatrogenic, diet, neuroendocrine, lifestyle, genetic, and socio-
behavioral factors, contribute to the development of obesity.
Among these, diet is the most important factor13. Many patho-
physiological mechanismsmight be involved in the development ofobesity and the metabolic alterations associated therewith14e16.
Insulin resistance is a key feature in the pathophysiology of the
metabolic complications in obese patients because resistance to
insulin action in various tissues, organ systems, and metabolic
pathways is common to these complications17. The HOMA-IR index
is used to quantify insulin resistance8. In our study, mice fed HFD
Figure 4. Effects of aging on high-fat diet (HFD)-induced liver injury. (A) Serum alanine aminotransferase (ALT) levels, (B) liver weights, and (C) nonalcoholic fatty liver disease
activity score (NAS) were determined by pathological examination of liver sections from 12 weeks of standard chow (CHOW) or HFD feeding in young (Y) and elderly (E) mice. (D)
Histopathological analysis of mice livers from the same animals (n¼ 6/group). Samples were stained with hematoxylin and eosin and examined by light microscopy (100).
Different superscript letters (a vs. b, a vs. c, b vs. c) indicate statistical signiﬁcance (p< 0.05).
Figure 5. Serum lipopolysaccharide (LPS) concentrations from 12 weeks of standard
chow (CHOW) or high-fat diet (HFD) feeding in young (Y) and elderly (E) mice (n¼ 6/
group). Different superscript letters (a vs. b) indicate statistical signiﬁcance (p < 0.05).
Figure 6. Changes in gut microbiota from 12 weeks of standard chow (CHOW) or high-
fat diet (HFD) feeding in young (Y) and elderly (E) mice. The mean Firmicutes/Bac-
teroidetes ratio was provided for each group (n¼ 4/group). Different superscript letters
(a vs. b, a vs. c, b vs. c) indicate statistical signiﬁcance (p< 0.05).
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structural alterations characterized by steatosis and an elevated
HOMA-IR index, compatible with the presence of insulin resistance.
Aged mice also demonstrated more severe insulin resistance, fat
mass accumulation, dyslipidemia, and steatohepatitis.
Chronic low-level inﬂammation, distinct from classical inﬂam-
mation, might cause obesity18. LPS, found in the outermembrane of
Gram-negative bacteria, can promote the development of obesity
and metabolic complications associated with an HFD19. Gut
microbiota are known to regulate fat storage20. Firmicutes and
Bacteroidetes are two dominant phyla in gut microbiota. The
interaction between these two phyla in the gut has been observed
in obesity (e.g., ob/obmice had a 50% reduction in the abundance of
Bacteroidetes and a proportional increase in Firmicutes compared
with lean mice)21. This trend is also observed in obese people who
have a higher proportion of Firmicutes/Bacteroidetes than do lean
people; the proportion reduced with weight loss following the
administration of low-calorie diet22. Our study showed that the
serum LPS level was signiﬁcantly higher in mice fed HFD than in
those fed the normal diet. A signiﬁcantly higher ratio of Firmicutes/
Bacteroidetes was also observed in the microbiota from fecal
samples of mice fed HFD. Interestingly, compared with young mice,
the ratio of Firmicutes/Bacteroidetes was also signiﬁcantly higher
in agedmice, but not the serum level of LPS. Therefore, other than a
gut microbial LPS-dependent mechanism, gut microbiota could
promote the development of more severe metabolic complications
in aged animals fed HFD.
Different rodent models for obesity and metabolic disorder
mostly focus on speciﬁc aspects of the different metabolic alter-
ations observed in obesity and metabolic syndrome at different
ages not comparable with human age5,6. Many studies have re-
ported that C57BL/6J mice fed an HFD develop obesity, insulin
resistance, diabetes mellitus, dyslipidemia, and fatty liver disease,
mimicking human obesity and metabolic complications in
obesity6,23. Compared with other rodent models such as Zucker
obese rats, ob/ob or db/db mice, or other gene-deletion animal
models, these HFD mice more closely resemble human obesity,
serving as a model of exogenous obesity as a result of a higher di-
etary caloric intake6,24. Estimated age ranges for mature life history
stages in C57BL/6J mice are mature adult (3e6 months old), middle
age (10e15 months old), and old (18e24 months old). In our study,
after the 12-week HFD feeding, mice aged 44 weeks were at the
early stages of old age, whereas mice aged 6 weeks were mature
adults. Our study revealed that compared with young C57BL/6J
mice fed HFD, aged mice could adequately and fully mimic the
range of signs of obesity and metabolic disorder characterized in
humans at adult and old ages. This aged obese model is applicable
not only as an adult model for studying obesity but also for aging.
Our study had some limitations. First, although cardiovascular
disease is a major metabolic complication in obesity, we did not
include any parameter for evaluating the presentation of cardio-
vascular diseases in obese mice. Second, different dietary models
display some of the signs of the metabolic damage5,6, but our
ﬁndings were restricted to rodent models and HFD-induced
metabolic disorders. Third, we provided a phenotype of aging
obese model for a multiple aspect study, but further studies on
mechanical relationships of obese, damaged organs, and aging are
lacking.
In conclusion, the ﬁndings of this study demonstrate that
metabolic damage that ensued from an HFD is affected by aging.
Physiological changes inherent to aging may promote the devel-
opment of advanced liver injury and inﬂammation, fat mass
deposition, dyslipidemia, insulin resistance, and even altered gut
microbiota composition. By establishing this aged obese model, a
further understanding of the mechanisms of these effects mayprovide new insights into the pathogenesis of HFD-induced meta-
bolic damage and metabolic syndrome in speciﬁc organs. This
could lead to speciﬁc targeted therapies for older patients.
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